Akorn, Inc., a leading specialty generic pharmaceutical company, announced that it has launched buprenorphine and naloxone sublingual tablets CIII in 2mg/0.5mg and 8mg/2mg strengths. This launch follows an October 15, 2015 Food and Drug Administration (FDA) approval for the product. Additionally, Akorn recently launched tobramycin injection, USP 40 mg/ml in 2 ml and 30 ml multi-dose vials. This launch follows a September 2014 approval for the product.
Akorn’s buprenorphine and naloxone sublingual tablets CIII in 2mg/0.5mg and 8mg/2mg strengths, marketed under the Hi-Tech Pharmacal label, are indicated for the maintenance treatment of opioid dependence. According to IMS Health, sales of Buprenorphine and Naloxone Sublingual tablets were approximately $312 million for the twelve months ended October 31, 2015.
Akorn’s tobramycin injection, USP, 40 mg/ml in 2 ml and 30 ml multi-dose vials, marketed under the Akorn label, are indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms included Septicemia in the paediatric patient and adult caused by P. aeruginosa, E. coli, and Klebsiella spp; lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase- and non-penicillinase-producing strains); serious central-nervous-system infections (meningitis) caused by susceptible organisms; intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp; skin, bone, and skin structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus; complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp, (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia spp, and Citrobacter spp.
According to IMS health, sales of all 40 mg/ml multi-dose vial presentations of Tobramycin Sulfate injection were approximately $5 million for the twelve months ended October 31, 2015.